Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.50 | 0.79 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.21 | 1.06 | 1.69 | 1.41 | 1.16 | 0.77 | 1.78 | 2.65 | 5.27 | 5.25 | 5.71 | 5.68 | 3.13 | 3.97 | 2.97 | 2.91 | 2.88 | 2.32 | 2.45 | 3.10 | 3.93 |
| — | +38.3% | -5.3% | -46.8% | -78.0% | -85.4% | -68.8% | -53.4% | +68.5% | +32.2% | +92.5% | +95.0% | +8.8% | +70.7% | +21.1% | -5.9% | -26.8% | -59.3% | -57.0% | -48.5% | -24.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 0.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -60.3% | 40.6% | -18.5% | -14.4% | -15.1% | -18.0% | -14.0% | -15.2% | -18.7% | -16.9% | -13.3% | -11.5% | -13.1% | -15.2% | -12.3% | -15.6% | -15.3% | -13.5% | -9.9% | -9.4% | -10.3% |
| — | +325.8% | -31.8% | +5.4% | +19.3% | -6.7% | -5.5% | -31.8% | -42.4% | -10.6% | -8.0% | +25.9% | +14.3% | -12.8% | -24.8% | -65.5% | -48.8% | -89.7% | -20.6% | +42.4% | +10.1% | |
| ROA | -52.0% | 34.8% | -15.5% | -12.2% | -12.8% | -15.5% | -12.3% | -13.1% | -15.9% | -14.7% | -11.6% | -10.2% | -11.7% | -13.5% | -10.9% | -13.8% | -13.6% | -12.2% | -9.0% | -8.6% | -9.4% |
| — | +325.1% | -25.8% | +7.0% | +19.7% | -4.9% | -5.5% | -27.9% | -36.1% | -9.4% | -6.5% | +25.6% | +14.2% | -10.3% | -21.8% | -59.9% | -44.6% | -96.4% | -30.5% | +34.5% | -11.4% | |
| ROIC | -62.4% | -18.4% | -16.6% | -13.5% | -12.9% | -14.5% | -13.6% | -15.3% | -15.7% | -13.8% | -11.3% | -11.8% | -13.6% | -12.8% | -11.8% | -18.3% | -21.1% | -15.3% | -11.5% | -13.1% | -14.5% |
| — | -26.7% | -22.7% | +11.5% | +18.3% | -5.7% | -19.8% | -29.3% | -16.1% | -7.1% | +4.0% | +35.5% | +35.8% | +16.0% | -2.3% | -39.9% | -46.2% | -62.6% | -9.4% | +26.7% | -40.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.07 | 0.10 | 0.09 | 0.08 | 0.07 | 0.06 | 0.06 | 0.08 | 0.07 | 0.06 | 0.05 | 0.05 | 0.06 | 0.06 | 0.05 | 0.06 | 0.06 | 0.05 | 0.05 | 0.05 |
| — | -5.5% | +69.1% | +63.0% | +2.7% | +6.1% | +4.7% | +8.3% | +67.1% | +6.5% | +6.2% | +8.9% | -22.6% | +9.7% | +3.0% | -6.1% | +29.9% | +1.4% | -59.2% | -59.4% | -83.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.38 | 9.24 | 6.12 | 6.38 | 7.30 | 6.39 | 9.19 | 9.30 | 6.05 | 7.79 | 10.47 | 7.80 | 13.35 | 9.09 | 10.83 | 9.29 | 10.31 | 13.41 | 15.68 | 17.69 | 17.36 |
| — | +44.8% | -33.4% | -31.4% | +20.8% | -18.0% | -12.3% | +19.2% | -54.7% | -14.3% | -3.3% | -16.1% | +29.5% | -32.3% | -30.9% | -47.4% | -40.6% | -20.7% | +34.5% | +18.4% | +137.8% | |
| Quick Ratio | 6.38 | 9.24 | 6.12 | 6.38 | 7.30 | 6.39 | 9.19 | 9.30 | 6.05 | 7.79 | 10.47 | 7.80 | 13.35 | 9.09 | 10.83 | 9.29 | 10.31 | 13.41 | 15.68 | 17.69 | 17.36 |
| — | +44.8% | -33.4% | -31.4% | +20.8% | -18.0% | -12.3% | +19.2% | -54.7% | -14.3% | -3.3% | -16.1% | +29.5% | -32.3% | -30.9% | -47.4% | -40.6% | -20.7% | +34.5% | +18.4% | +137.8% | |
| Interest Coverage | -116.99 | 279.72 | -99.62 | -11.86 | -105.41 | -144.71 | -128.94 | -126.54 | -140.65 | -146.87 | -130.75 | -125.94 | -130.98 | -139.39 | -123.65 | -144.19 | -92.00 | -62.18 | -40.29 | -34.01 | -38.22 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RCKT stock.
Rocket Pharmaceuticals, Inc.'s current P/E is -1.5x. The average P/E over the last 1 quarters is 0.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Rocket Pharmaceuticals, Inc.'s business trajectory between earnings reports.